We have added these links to the SRL and Metropolis section of web sites. As you can see the two largest Diagnostics companies in India are selling Onko-Sure..SRL Limited and Metropolis Healthcare., Our sources told us that Metropolis is using the brand name Cancer 8 because SRL is using Onko-Sure.The 10 Million dollar deal with the India Government that was delayed in 2011 has apparently come to fruition. Radient had not filed their 2012,2013,2014 for a reason. To act like a private company without having to show the revenues from the India deal. The Indian deal consummated in 2013. On February 1, 2013, SRL sent out the first hint of the 10 million deal. Some will call this "India hype" or marijuana hype, whatever name was convenient at the time to falsely identity the true reasons for Large buying trading days over a two and a half years of accumulation... Too Funny ...DC Remember unknown Julie from the ahoooo board? Remember she was used to start the topic of the day...Deja Vu...Unknown Julie is now Unknown Jimmy Mac when are you coming back..you understand. Always has been..lol Ahoooooooooooooooooooooooooooooooooooooooooooooo
Tomorrow we will show how the Creeping Takeover groups accumulated the Radient and today own 57 to 60 percent or more of the 4.5 billion outstanding shares. They did it in35 trading days from July 10, 2012 up to July 3, 2014..In two years..here is a hint..On July 10, 2012 and July 11 619 million shares traded...What was signed on July 12, 2012 and reported in a *-K on July 17, 2012...The start of the Angel investors you understand...ahooooooooooooooooooooooooo
Radient is being restructured by a reverse merger. The majority of the stock is owned by institutional investors and Provista Diagnostics Angel investors. Someone mentioned that Radient was BROKE and should have gone bankrupt in June 2011 when indeed Radient was not in a bankrupt situation and to this day has never been. In Late September 2011, Radient was able to pay Alpha Capital the major 2011 lender 4.581,923 for the 4,559,842 million dollars to settle the 10.9 million owed to the :2011 lenders. The cash payment included 22,000 dollars of interest for one month after the settlement. The notes payable is reflected in the balance sheet from the last 10-K ending December 31, 2011.The remaining 6.0 million was converted into Radient stock by all of the 2011 lenders. The conversion took place after May 21, 2012 at .001 per share. On May 21, 2012 Alpha and Whalehaven filed their SC 13 G's. In the settlement agreement the 2011 lenders were able to convert at .0001 per share.. The conversions started on May 25, 2012, according to the settlement before the 1/25 reverse split, Alpha was given 11,886,000 shares with protection, giving them 295 million shares. Whalehaven was given 9,114,000 shares which gives them after the reverse split, 127,850 million shares. In the agreement the 2011 collectively could not own more than 9.99 percent of the outstanding Radient stock..The 2011 at this time own 9.99 per cent of the RXPC stock and still holding. There is no way they would have converted at .001 and sold at .0001..That would give them less than 42,000 dollars...
The pps of the stock was at .02 before the conversions took place. The SC 13G's were filed on May 21, 2012..The conversions at .001 took place on May 25, 2012.
Jun 1, 2012 0.00 0.00 0.00 0.00 378,592,700 0.00 May 31, 2012 0.00 0.00 0.00 0.00 263,543,400 0.00 May 30, 2012 0.00 0.00 0.00 0.00 77,692,000 0.00 May 29, 2012 0.00 0.00 0.00 0.00 251,389,600 0.00 May 28, 2012 0.00 0.00 0.00 0.00 0 0.00 May 25, 2012 0.00 0.00 0.00 0.00 207,965,300 0.00 May 24, 2012 0.00 0.00 0.00 0.00 46,605,000 0.00 May 23, 2012 0.01 0.01 0.00 0.00 14,010,300 0.00 May 22, 2012 0.01 0.01 0.01 0.01 9,183,400 0.01 May 21, 2012 0.02 0.02 0.01 0.01 11,104,400 0.01
Under the terms of the Final Settlement Agreement, we issued our 8% convertible promissory notes in the principal amount of $4,559,842.41 to Alpha Capital and $3,496,415.91 to Whalehaven (the “Notes”). We are obligated retire the Notes in monthly installments, commencing January 31, 2012, by the payment in cash or (at our sole option) by delivery shares of our common stock in an amount equal to 6.25% of the principal amount of each Note, plus accrued interest. In the event we elect to make installment payments in common stock, we will be obligated to make monthly delivery of shares of common stock that are not subject to any restrictions on resale under Rule 144 under the Securities Act (“Non-Restricted Shares”) valued at 80% of the three lowest volume weighted average closing prices of our common stock over the 20 trading days immediately prior to each installment payment date. It is our present intention to amortize the Notes with our common stock, although we may elect to pay one or more such installments in cash. ,
The Notes permit the Plaintiffs to convert the Notes into our common stock, although the Final Settlement Agreement and the Notes contain “blocker” provisions designed to prevent the Plaintiffs from becoming “beneficial owners” (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act “) of more than 9.99% of our outstanding common stock, the Plaintiffs
We agreed to reserve an aggregate of 175.0 million shares of authorized and previously unissued Common Stock for potential issuance to the Plaintiffs for issuance upon their conversion of the Notes. We further agreed to keep a sufficient number of shares of Common Stock for purposes of enabling issuing all of the Settlement Shares pursuant to the Final Settlement Agreement and the Notes.
This Final Settlement Agreement (the “Final Agreement”) is dated this 25th day of August 2011, to be effective as of August 19, 2011 (the “Effective Date”), is being entered into among Radient Pharmaceuticals Corporation (“RPC” or the “Company”), Whalehaven Capital Fund, Ltd. (“Whalehaven”) and Alpha Capital Anstalt (“Alpha Capital,” and together with Whalehaven, the “Plaintiffs” or the “Holder(s)”). The Company and the Holders are hereinafter sometimes collectively referred to as the “Parties.”
§ “Common Stock” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.
“Converted Alpha Capital Notes” means notes aggregating $1,616,380.92 that were converted by Alpha Capital as part of the Initial Share Conversions into an aggregate of 11,886,000 Settlement Shares.
Converted Whalehaven Notes” means notes aggregating $1,239,415.76 that were converted by Whalehaven as part of the Initial Share Conversions into an aggregate of 9,114,000 Settlement Shares.
“Non-Restricted Shares” means shares of RPC Common Stock that are freely tradable, delivered without any restrictive legend and immediately resellable upon receipt by the Holder thereof pursuant to Rule 144(b)(1)(i) under the Securities Act of 1933, as amended, after November 2, 2011 without any additional holding period, volume limitations or manner of sale restrictions.
“Settlement Amount” shall mean the aggregate sum of $10,912,055 payable by the Company to the Plaintiffs under the Settlement Agreement and this Final Agreement, as to Alpha Capital in the amount of $6,176,223.13 and as to Whalehaven in the amount of $4,735,831.87.
FOR VALUE RECEIVED, RADIENT PHARMACEUTICALS CORPORATION, a Delaware corporation (hereinafter called “Debtor”), hereby promises to pay to the order of ALPHA CAPITAL ANSTALT (the “Holder”), with an address at Pradafant 7, 9490 Furstentums, Vaduz, Lichtenstein, Fax: 011-42-32323196, without demand, the sum of Four Million Five Hundred Fifty Nine Thousand Eight Hundred Forty Two Dollars Forty One Cents ($4,559,842.41) (“Principal Amount”), with interest accruing thereon, on April 15, 2013 (the “Maturity Date”), if not sooner paid or modified as permitted herein.
This Convertible Promissory Note (the “Note”) has been entered into pursuant to the terms of a Final Settlement Agreement by and among the Debtor, the Holder and another holder (the “Other Holder”) of a convertible promissory note (the “Other Note”), dated of even date herewith (the “Final Settlement Agreement”), for an aggregate Principal Amount of $8,056,258.32. Unless otherwise separately defined herein, each capitalized term used in this Note shall have the same meaning as set forth in the Final Settlement Agreement. The following terms shall apply to this Note:
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
6,496,317 shares of Common Stock 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.99%
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x
The aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction.
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -
6,496,317 shares of Common Stock 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES x
The aggregate amount in Row 9 represents the maximum amount of shares that Whalehaven Capital Fund Limited can beneficially control under a contractually stipulated 9.99% ownership restriction. 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
We have concluded from the planned merger between Radient and Provista Diagnostics according to the LOI of 2010 and our completed analysis that Provista Diagnostics will either merge with Radient or reverse triangular merge Global Cancer Diagnostics with Radient. The agreement between AMDL Diagnostics and Uni-Pharma and the agreement between Radient and Global Cancer Diagnostics were set up on a temporary basis and conveniently terminated after the last patent expired. Radient and Provista Diagnostics still have an exclusive 5 year agreement in force and Radient and Uni-Pharma are also in an exclusive and existing five year agreement. Those two agreements superseded the two previously terminated agreements. The Lung Cancer Test a/k/a LC Sentinel is still owned by Radient and Provista Diagnostics and included in their 5 year exclusive and collaborated agreement from November 2010 to research, develop, and commercialize cancer tests including the Lung Cancer Test. William Gartner sold his lung cancer and breast cancer to Provista Diagnostics in 2011. The 4.5 billion RXPC shares outstanding are held by Institutional investors who had converted their debt for equity, and Angel investors who we believe are associated with Provista Diagnostics. After the announcement of revocation and insolvency, RXPC shares were accumulated and not sold. During the 2012 to July 3, 2014 period of trading,the creeping take over groups quietly took all the shares that Radient released slowly and in a timely manner to the public. If "ebabies" retailers etc that some are calling them were buying,they would have been the first to sell shares. As you can see from the lack of interest on this board before 2012 and after 2013...Enjoy our deductive logic approach to our premisses....
"Radient Is Being Restructured By A Planned Reverse Merger."
If:Radient wants and needs to be restructured by a merger and not by bankruptcy.
Then:Provista Diagnostics wants to go public
Therefore:Provista Diagnostics will merge according to the planned merger LOI of 2010 and the planned restructuring of Radient
*Uni-Pharma-Radient Dx Current Agreements and Past Agreement
*All Accounts Payable Paid in Full By GCDx and Uni-Pharma Royalties/ License Agreements,Onko-Sure Sales in India,Taiwan,Korea,etc.and Attorney Debt to Equity Agreement
News 
Market Data 
Discover 
AI
